Comparative Pharmacology
Head-to-head clinical analysis: MUPIROCIN versus MYCHEL S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MUPIROCIN versus MYCHEL S.
MUPIROCIN vs MYCHEL-S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, inhibiting protein synthesis.
Sulconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Apply a small amount of 2% ointment or cream to affected area three times daily for 5 to 14 days.
200 mg orally every 12 hours for 14 days
None Documented
None Documented
Intravenous: ~30 min (0.5 h). Topical: systemically absorbed amount negligible, local half-life not defined.
3-4 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Clinical Note
moderateMupirocin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mupirocin."
Renal: <1% unchanged (topical); hepatic metabolism to monic acid, eliminated renally and fecally. After IV administration, 60-70% renal, 20-30% fecal/biliary.
Renal: 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Category A/B
Category C
Antibiotic
Antibiotic